Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Sarcoma 1Non-squamous Non-small-cell Lung Cancer 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Tumors 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

Injections 3pembrolizumab 2olaparib 2atezolizumab 2Leucovorin 2Irinotecan 2ulixertinib 1toripalimab 1tipifarnib 1sotorasib 1serabelisib 1mirdametinib 1famitinib 1camrelizumab 1adagrasib 1Taxes 1Ramucirumab 1Radiation 1Paclitaxel 1IFL protocol 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Docetaxel 1Bevacizumab 1BID protein, human 1Appointments and Schedules 1Albumin-Bound Paclitaxel 1APG-1387 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumor × camrelizumab × Clear all
NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡